ACE2 and COVID-19: Finally, predicted changes in the Ang(1-7) production rate with ACEi/ARB therapy, comorbidities, or infection were all minimal compared to the exogenous Ang(1-7) infusion rates demonstrated experimentally to protect against acute lung injury, suggesting that changes in the ACE2-Ang(1-7)-Mas arm may not be significant enough to play a role in COVID-19 pathology [29].